February 2018

Contents

Editorial

23 February 2018: vol 19 no 4

09 February 2018: vol 19 no 3

Conference reports

CROI 2018 – highlights from the preliminary programme

Antiretrovirals

FDA grants tentative approval to first DTG/FTC/TAF FDC

Bictegravir approved in the US in new integrase-inhibitor based FDC (Biktarvy)

US approve a lower-dose efavirenz (400 mg) based generic FDC (Simfi Lo)

ViiV announces phase 3 study switching to dolutegravir/3TC dual therapy from TAF-containing ART

US darunavir label updated: drug interactions and pregnancy

Treatment access

Universal ART on diagnosis: approved by NHS England

75% of WHO essential medicines could be cheaper: UK and South Africa both overpay

London clinic to prescribe generic PrEP privately at £55 for 30 tablets

Pregnancy

Standard once-daily dolutegravir dosing achieves target levels during pregnancy

New HIV pregnancy study uses latest ART: IMPAACT 2010 study (VESTED) includes dolutegravir and tenofovir alafenamide (TAF)

Association between timing of maternal ART and risk of infants born small for gestational age in Dutch ATHENA cohort

PK and drug interactions

Significant drug-drug interaction between dolutegravir and isoniazid-rifapentine

Guidelines

BHIVA standards of HIV care (2018): online for comment

UK HIV pregnancy guidelines (2018): online for comment

Side effects

Meta-analysis reports no significant risk of cardiac, IRIS or suicide with dolutegravir

Cure-related research

New data on identifying and targeting the latent HIV reservoir

Recruiting natural killer cells to target HIV persistence

Other news

Discrimination against gay men overturned with new HPV vaccine programme for England

UK study highlights discrimination against trans people living with HIV

On the web

PrEP resources for access

HIV conversations in the UK

Women in Science: IAS feature

Yale CRIT conference: blogs on the threats from changes to drug regulation in the US and Europe

PDFs

23 February 2018: vol 19 no 4

09 February 2018: vol 19 no 3